Navigation Links
Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
Date:7/31/2008

DUSSELDORF, Germany, August 1 /PRNewswire-FirstCall/ --

- Further Focus on Pharma & Life Science

Gerresheimer AG is to discontinue its business in technical plastic systems. The business segment, which primarily manufactures system components for suppliers to the automobile industry, is not part of the core business of pharma & life science. For this purpose the sale process has been started through an international invitation for bids.

"Through the sale of the technical plastics business we are, as previously announced, continuing our focus on the core business of pharma & life science, "says Dr. Axel Herberg, CEO of Gerresheimer AG.

In the segment of technical plastic systems, Gerresheimer employs 550 people at locations in Germany, the Czech Republic and Mexico as well as through joint ventures in Italy and Bulgaria, manufacturing system components for suppliers to the automobile industry. The main product focus is on vehicle electrics, powertrain and chassis as well as interior. Sales of around EUR 70m are expected for this segment in the financial year 2008.

Gerresheimer acquired the technical plastics business in 2007 as part of the Wilden Group. While the Wilden Group's business in medical plastic systems has today been firmly integrated in the Gerresheimer Group's portfolio, the technical plastics segment does not belong to Gerresheimer's core business in pharma & life science. Through the sale, portfolio rationalisation in the Plastic Systems Division will be completed.

In June this year, the Dusseldorf company already sold off its consumer healthcare business, which also did not fit in with its core business.

About Gerresheimer

Gerresheimer employs more than 10,300 people in 40 locations in Europe, America and Asia. In the financial year 2007, worldwide sales totalled EUR 958m. The product portfolio ranges from pharmaceutical vials made of glass and plastic through to complex drug-delivery syst
'/>"/>

SOURCE Gerresheimer AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Gerresheimer Further Increases its Sales and Earnings Power
2. Gerresheimer Discontinues Marginal Operations
3. Moodys Raises Rating for Gerresheimer
4. Gerresheimer: Record Year in 2007 and Positive Outlook for 2008
5. 2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer
6. Yves Lionel Assant is New Chairman of Gerresheimers Supervisory Board
7. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
10. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
11. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... made great strides in saving China,s endangered national treasure, ... 65 giant panda reserves that have been established and ... 1596 pandas remain in the wild. , Breeding ... the panda by improving genetic diversity, avoid inbreeding and ... are these high-profile programs doing so far? , In ...
(Date:7/23/2014)... Shimadzu Scientific Instruments has launched the ... developed jointly with Ajinomoto Co. Inc. Offering simultaneous ... amino acids in nine minutes, drastically enhancing laboratory ... utilizing a fast application-specific column and an LCMS-2020 ... even under conditions with difficult samples that contain ...
(Date:7/23/2014)... AVIV, Israel , July 23, 2014 /PRNewswire/ ... ., a portfolio company of Trendlines Agtech ... one of Israel,s leading ... http://photos.prnewswire.com/prnh/20140121/666259-a) , Valentis,s technology combines nanocrystalline ... plant pulp waste, with additional nanoparticles to produce ...
(Date:7/23/2014)... 2014  GrowBLOX Sciences, Inc. (OTCQB: GBLX), a medical cannabis ... for two medical marijuana dispensary locations in Las ... the Clark County, Nevada dispensary for ... previously announced.  GrowBLOX Sciences, CEO Craig Ellins ... applications for dispensaries in the City of Las ...
Breaking Biology Technology:Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3
... 3 ,HemoGenix(R) and ORF Genetics announce the collaboration ... for use in all HALO(R),Assay Kits and HALO(R) ... cells is detected. , ... of growth factors and cytokines using,barley seed as ...
... , QUEBEC CITY, Dec. ... AEZS ; TSX: AEZ), a global biopharmaceutical company focused ... completed the transaction under the previously announced purchase and ... relating to AEterna Zentaris, rights to royalties on future ...
... announces the exclusive licensing of DxS Scorpions™ technology to test for ... and targeted control of contaminant microbes can increase profitability. , ... ... ETS has had the exclusive license to use this technology in ...
Cached Biology Technology:HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Research Services 2HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Research Services 3AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 2AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 3ETS Laboratories Offers New Process Optimization Tools to the Fuel Ethanol Industry 2
(Date:7/23/2014)... using tissue samples cultured from cystic fibrosis patients, scientists ... Marsico Lung Institute have shown that a new CF ... CF drug. , The finding, published today in the ... mutant CFTR protein becomes unstable and loses its ability ... two drugs. The research offers several insights into how ...
(Date:7/23/2014)... , , , , ... , , , , ... extend healthy lifespan. The idea, they argue, would be to target the... , , ... , , , , , ... , , , , , , , Medicine focuses almost ...
(Date:7/23/2014)... Roughly 780 million people around the world have no ... Health Organization (WHO), 3.4 million people die from water-related ... the goal of making a contribution to solving this ... Wendelin Stark, head of the Functional Materials Laboratory, the ... developing a prototype. , "What makes our DrinkPure filter ...
Breaking Biology News(10 mins):UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5ETH student develops filter for clean water around the world 2
... Boston, MA (Jan. 18, 2012) The National ... Research Institute, a subsidiary of Mass. Eye and Ear, ... understand the origins of eye allergies (NEI Grant Number ... principal investigator for the project formally entitled "Cellular and ...
... new approach to motion capture technology is offering fresh ... general. Researchers studied three types of tennis serves, ... which creates the highest potential for shoulder injury. ... Annals of Biomedical Engineering , could aid sports training ...
... of microbiologists led by Indiana University researchers has identified a ... single end or pole of the cell instead of uniform, ... that could have implications in the development of new antibacterial ... bacteria such as Escherichia coli and Bacillus ...
Cached Biology News:Markerless motion capture offers a new angle on tennis injuries 2Markerless motion capture offers a new angle on tennis injuries 3Markerless motion capture offers a new angle on tennis injuries 4Polar growth at the bacterial scale reveals potential new targets for antibiotic therapy 2Polar growth at the bacterial scale reveals potential new targets for antibiotic therapy 3
Recorder, 6", 7 Day, 1 Pen, 0 to 100°C, 220V, 50/60 Hz, for 4520, Customer Installed...
... Serotec STAR3000 HISTAR detection systems ... to be used with species specific ... in tissue specimens. Visualisation is accomplished ... that utilises novel polymer labelling technology. ...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
... AmpliTaq DNA Polymerase is ... the PCR process, a testimony to its ... activity profile makes it ideal for PCR ... to guarantee reproducible results. ,, AmpliTaq ...
Biology Products: